Shares of Solventum Co. (NYSE:SOLV – Get Free Report) have been given a consensus rating of “Hold” by the eleven brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $68.29.
A number of analysts have recently commented on SOLV shares. Stifel Nicolaus started coverage on Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. Piper Sandler boosted their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Mizuho began coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target on the stock. Finally, Morgan Stanley lifted their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th.
Check Out Our Latest Report on SOLV
Institutional Investors Weigh In On Solventum
Solventum Stock Down 0.7 %
NYSE SOLV opened at $73.57 on Tuesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum has a 52 week low of $47.16 and a 52 week high of $96.05. The stock has a fifty day moving average of $70.17 and a 200-day moving average of $67.43.
Solventum (NYSE:SOLV – Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.23). The business had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Analysts forecast that Solventum will post 6.58 EPS for the current year.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
See Also
- Five stocks we like better than Solventum
- Following Congress Stock Trades
- How to Invest in Small Cap Stocks
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- These Are the Dividend Stocks Insiders Bought in January
- Investing in the High PE Growth Stocks
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.